Ocumension Therapeutics

01477

Company Profile

  • Business description

    Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

  • Contact

    No. 1858 Yinzhongnan Road
    Guoxiang Subdistrict
    Wuzhong District
    SuzhouJiangsu
    CHN

    T: +86 2161493800

    https://www.ocumension.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    505

Stocks News & Analysis

stocks

Microsoft earnings: Strong, including Azure, but overall guidance is in line

We think Microsoft stock is moderately undervalued.
stocks

After earnings, is Tesla stock a buy, a sell, or fairly valued?

Q3 earnings reflected sequential improvement driven by record auto deliveries and energy storage deployments.
stocks

3 cheap fully franked stocks

Well priced Aussie shares that offer a tax rebate.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,178.905.000.05%
CAC 408,147.3553.53-0.65%
DAX 4024,118.895.32-0.02%
Dow JONES (US)47,522.12109.88-0.23%
FTSE 1009,721.0635.08-0.36%
HKSE26,282.6963.45-0.24%
NASDAQ23,581.14377.33-1.57%
Nikkei 22551,325.6117.960.04%
NZX 50 Index13,489.8930.600.23%
S&P 5006,822.3468.25-0.99%
S&P/ASX 2008,885.505.500.06%
SSE Composite Index3,986.9029.43-0.73%

Market Movers